{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T16:29:10Z","timestamp":1775147350997,"version":"3.50.1"},"reference-count":33,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropediatrics"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Introduction\u2003We evaluated the effect of nusinersen on clinical and laboratory parameters and presented its safety and effect on laboratory parameters.<\/jats:p><jats:p>\n          Methods\u2003Two groups were formed from among patients with spinal muscular atrophy (SMA) followed up between September 2017 and June 2021: group 1, SMA type 1; group 2, SMA type 2 and 3. The laboratory parameters were evaluated in groups 1 and 2 between doses. Motor scale tests were performed on patients before each dose of nusinersen.<\/jats:p><jats:p>\n          Results\u2003Twenty seven patients (group 1; n\u2009=\u200913, group 2; n\u2009=\u200914) were included. The mean age (\u00b1standard deviation) at the onset of symptoms was 3\u2009\u00b1\u20091.21 (range, 1.5\u20136) months in group 1 and 12\u2009\u00b1\u20094.27 (range, 8\u201324) months in group 2. No significant laboratory treatment-related abnormalities and adverse effects were observed. The cerebrospinal fluid protein levels and the frequency of conventional LP were higher in group 1. Serum creatinine (Cr) levels were higher in group 1 before the first dose and higher in group 2 before the fifth dose (p\u2009&lt;\u20090.05). With treatment, the Cr levels of group 1 decreased and group 2 remained constant or increased. We observed that the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders and Hammersmith Functional Motor Scale-Expand scores increased as our patients received treatment (p\u2009&lt;\u20090.05).<\/jats:p><jats:p>\n          Conclusion\u2003Our results support the safety and efficacy of nusinersen. However, changes in Cr levels according to the clinical type and treatment suggested that serum Cr could be a candidate marker for treatment follow-up.<\/jats:p>","DOI":"10.1055\/s-0042-1750719","type":"journal-article","created":{"date-parts":[[2022,7,24]],"date-time":"2022-07-24T22:31:58Z","timestamp":1658701918000},"page":"321-329","source":"Crossref","is-referenced-by-count":9,"title":["The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy"],"prefix":"10.1055","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-9995","authenticated-orcid":false,"given":"Gamze","family":"Sar\u0131kaya Uzan","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Dokuz Eyl\u00fcl University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Paket\u00e7i","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Dokuz Eyl\u00fcl University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-6297","authenticated-orcid":false,"given":"\u00c7a\u011fatay","family":"G\u00fcnay","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Dokuz Eyl\u00fcl University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0395-7866","authenticated-orcid":false,"given":"P\u0131nar","family":"Edem","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Dokuz Eyl\u00fcl University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zlem","family":"\u00d6zsoy","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Dokuz Eyl\u00fcl University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semra","family":"H\u0131z Kurul","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Dokuz Eyl\u00fcl University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulu\u00e7","family":"Yi\u015f","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Pediatrics, Dokuz Eyl\u00fcl University Faculty of Medicine, \u0130zmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,7,24]]},"reference":[{"issue":"01","key":"ref1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy\u2014a literature review","volume":"12","author":"I EC Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: promises and challenges","volume":"14","author":"E JN Groen","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"ref3","year":"2017"},{"issue":"07","key":"ref4","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience","volume":"31","author":"M Hach\u00e9","year":"2016","journal-title":"J Child Neurol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"R S Finkel","year":"2016","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"C F Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","article-title":"Antisense oligonucleotides: from design to therapeutic application","volume":"33","author":"J H Chan","year":"2006","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0192623314551840","article-title":"Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective","volume":"43","author":"K S Frazier","year":"2015","journal-title":"Toxicol Pathol"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.taap.2004.04.017","article-title":"Toxicology of antisense therapeutics","volume":"201","author":"T L Jason","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1007\/s00415-021-10569-8","article-title":"Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters","volume":"268","author":"B Stolte","year":"2021","journal-title":"J Neurol"},{"issue":"06","key":"ref11","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/mus.27217","article-title":"Laboratory monitoring of nusinersen safety","volume":"63","author":"N L Goedeker","year":"2021","journal-title":"Muscle Nerve"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated safety assessment of 2\u2032-o-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers","volume":"24","author":"S T Crooke","year":"2016","journal-title":"Mol Ther"},{"issue":"03","key":"ref13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The effects of 2\u2032-o-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials","volume":"27","author":"S T Crooke","year":"2017","journal-title":"Nucleic Acid Ther"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1515\/cclm-2015-0253","article-title":"Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity","volume":"54","author":"H Hegen","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1373\/clinchem.2017.278267","article-title":"Cerebrospinal fluid total protein reference intervals derived from 20 years of patient data","volume":"63","author":"C R McCudden","year":"2017","journal-title":"Clin Chem"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0022-510X(91)90218-V","article-title":"Age-related changes in cerebrospinal fluid protein concentrations","volume":"104","author":"M J Garton","year":"1991","journal-title":"J Neurol Sci"},{"issue":"04","key":"ref17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ejpn.2017.03.006","article-title":"Validated age-specific reference values for CSF total protein levels in children","volume":"21","author":"V Kahlmann","year":"2017","journal-title":"Eur J Paediatr Neurol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fneur.2019.01179","article-title":"Routine cerebrospinal fluid (CSF) parameters in patients with spinal muscular atrophy (SMA) treated with nusinersen","volume":"10","author":"C D Wurster","year":"2019","journal-title":"Front Neurol"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/brainsci11030296","article-title":"Cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients","volume":"11","author":"L H M\u00fcschen","year":"2021","journal-title":"Brain Sci"},{"issue":"11","key":"ref20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"D C De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"18","key":"ref21","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"R S Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"E Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"e0148495","DOI":"10.1371\/journal.pone.0148495","article-title":"A new equation to estimate muscle mass from creatinine and cystatin C","volume":"11","author":"S W Kim","year":"2016","journal-title":"PLoS One"},{"issue":"09","key":"ref24","doi-asserted-by":"crossref","first-page":"e921","DOI":"10.1212\/WNL.0000000000008762","article-title":"Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy","volume":"94","author":"C RR Alves","year":"2020","journal-title":"Neurology"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/acn3.51340","article-title":"Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment","volume":"8","author":"M Freigang","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40263-019-00656-w","article-title":"An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with nusinersen in seven clinical trials","volume":"33","author":"B T Darras","year":"2019","journal-title":"CNS Drugs"},{"issue":"08","key":"ref27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-020-04148-6","article-title":"Safety of bedside lumbar puncture in adult patients with thrombocytopenia","volume":"99","author":"A J Portuguese","year":"2020","journal-title":"Ann Hematol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","article-title":"Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients","volume":"27","author":"L Szab\u00f3","year":"2020","journal-title":"Eur J Paediatr Neurol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"34635","DOI":"10.1038\/srep34635","article-title":"Survival motor neuron (SMN) protein is required for normal mouse liver development","volume":"6","author":"E Szunyogova","year":"2016","journal-title":"Sci Rep"},{"issue":"02","key":"ref30","first-page":"103","article-title":"What does a hemogram say to us?","volume":"55","author":"T T Celkan","year":"2020","journal-title":"Turk Pediatri Ars"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","article-title":"Longitudinal natural history of type I spinal muscular atrophy: a critical review","volume":"15","author":"E Mercuri","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"09","key":"ref32","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","article-title":"Gain and loss of abilities in type II SMA: a 12-month natural history study","volume":"30","author":"G Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"D Osredkar","year":"2021","journal-title":"Eur J Paediatr Neurol"}],"container-title":["Neuropediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1750719.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T23:31:13Z","timestamp":1665531073000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1750719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,24]]},"references-count":33,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2022,10,11]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1750719","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0174-304X","1439-1899"],"issn-type":[{"value":"0174-304X","type":"print"},{"value":"1439-1899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,24]]}}}